Market Movers: Analyzing Today's Top Stock Losers in Biotech, Semiconductors, and AI

Font: Financial Modeling Prep  • May 18, 2026

• Biopharmaceutical firms like Edesa Biotech, Inc. (NASDAQ:EDSA) and Design Therapeutics, Inc. (NASDAQ:DSGN) experienced significant stock declines due to financial reports and clinical data.
• The semiconductor sector saw Trio-Tech International (AMEX:TRT) shares fall, while AI-focused RoboStrategy, Inc. (NASDAQ:BOT) dropped despite new funding, raising dilution concerns.
• Leveraged ETFs, such as The Daily Target 2X Long HIMS ETF (ARCA:HIMZ), mirrored underlying stock losses, indicating broader market impacts on specific companies like Hims & Hers Health, Inc. (NYSE:HIMS).

The market sees several major losers today, including biopharmaceutical firms. Edesa Biotech, Inc. (NASDAQ:EDSA) stock falls 31.03% to $9.00 following its recent second-quarter financial report and business update. The company is currently advancing a Phase 3 drug for acute respiratory distress syndrome in COVID-19 patients.

Design Therapeutics, Inc. (NASDAQ:DSGN) also declines 25.54% to $10.70 after its shares wobbled following the release of new data on a rare genetic disease. In the semiconductor sector, Trio-Tech International (AMEX:TRT) shares decrease 24.04% to $15.23. Trio-Tech International provides manufacturing and testing services to the industry.

RoboStrategy, Inc. (NASDAQ:BOT), an AI-focused investment company, sees its stock drop 21.24% to $28.36. The fall occurs despite news of a new $2 billion equity facility. This type of funding lets a company sell shares over time, which can concern investors about the value of their existing shares being diluted.

The Daily Target 2X Long HIMS ETF (ARCA:HIMZ) falls 21.97% to $22.44. As a leveraged ETF, it aims to provide two times the daily return of Hims & Hers Health, Inc. (NYSE:HIMS) stock. The sharp drop in HIMZ indicates that the underlying Hims & Hers stock also experienced a significant loss today.

In summary, today's declines are tied to specific company events. Biotech firms reacted to financial results and clinical data. Other stocks fell despite seemingly positive news, highlighting complex investor reactions to events like new funding agreements and their potential impact on share value.